Cytos Biotechnology AG

DGAP-Adhoc: Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd: Shareholders approved all resolutions

Cytos Biotechnology AG  / Key word(s): Capital Increase

04.11.2013 12:29

Release of an ad hoc announcement pursuant to Art. 53 KR

Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd:
Shareholders approve all resolutions

Schlieren (Zurich), Switzerland, November 4, 2013 - Cytos Biotechnology Ltd
(SIX:CYTN) today announced that its shareholders have approved all
resolutions at the Extraordinary Shareholders' Meeting the announced
capital increase in particular.

The Extraordinary Shareholders' Meeting of Cytos Biotechnology Ltd took
place at the company's headquarters in Schlieren (Zurich), Switzerland. It
was attended by 28 shareholders. 12,673,384 shares or 56.55% of a total of
22,411,431 shares were represented.

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of
targeted immuno-therapies. The Company's lead product candidate CYT003 is a
novel, first-in-class, immune modulator in Phase 2 clinical development as
a potential new treatment for asthma.CYT003 has a novel mechanism of action
that inhibits the immune response that causes asthma, and may therefore be
beneficial for the control of asthma. In a successfully completed Phase 2a
study, CYT003 was shown to maintain asthma control and lung function in
patients with persistent allergic asthma, despite withdrawal of standard
therapy with inhaled corticosteroids. CYT003 has been shown to have a good
safety and tolerability profile in more than 450 individuals receiving the
active agent so far.Cytos was founded in 1995 as a spinoff from the Swiss
Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren
(Zurich), Switzerland. The Company is listed according to the Main Standard
on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements

This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements.  You are urged to consider
statements that include the words 'will' or 'expect' or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, including that CYT003
may not demonstrate safety or efficacy in clinical trials, that there may
be delays in development or that CYT003 may not receive marketing approval,
and that the Company relies on outside financing to meet capital
requirements, which may not be available under acceptable terms or at all.
Against the background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or

Additional features:

Document title: Cytos_Press_EGM_2013

04.11.2013 News transmitted by EQS Schweiz AG.
The issuer is responsible for the contents of the release.

EquityStory publishes regulatory releases, media releases on the capital
market and press releases.
The EquityStory Group distributes authentic and real-time financial news
for over 1'300 listed companies.
The Swiss news archive can be found at


Language:               English
Company:                Cytos Biotechnology AG
                        Wagistr. 25
                        8952 Schlieren
Phone:                  +41 44 733 4747
Fax:                    +41 44 733 4740
ISIN:                   CH0011025217, CH0029060735
Valor:                  -
Listed:                 Freiverkehr in Berlin, München, Stuttgart;
                        Frankfurt in Open Market ; SIX

End of Announcement                             EQS Group News-Service



Weitere Meldungen: Cytos Biotechnology AG

Das könnte Sie auch interessieren: